Crossmark

CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival

Crossref DOI link: https://doi.org/10.1186/s40478-018-0521-5

Published Online: 2018-03-01

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zeiner, P. S.

Zinke, J.

Kowalewski, D. J.

Bernatz, S.

Tichy, J.

Ronellenfitsch, M. W.

Thorsen, F.

Berger, A.

Forster, M. T.

Muller, A.

Steinbach, J. P.

Beschorner, R.

Wischhusen, J.

Kvasnicka, H. M.

Plate, K. H.

Stefanović, S.

Weide, B.

Mittelbronn, M.

Harter, P. N.
More Information

Article History

Received: 17 February 2018

Accepted: 18 February 2018

First Online: 1 March 2018

Ethics approval and consent to participate

: Written consent was obtained from each patient. The study protocol was endorsed by the local ethical committee (Goethe-University Medical School/UCT Frankfurt GS-04/09, SNO-08-2015).

: Not applicable.

: The authors declare that they have no conflict of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.